Stockscreener 앱 받기
1.48
7.25%
0.10
전일 마감가:
$1.38
열려 있는:
$1.37
하루 거래량:
191.85K
Relative Volume:
0.99
시가총액:
$4.52M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-8.92%
1개월 성능:
-20.43%
6개월 성능:
-62.53%
1년 성능:
-95.89%
1일 변동 폭
$1.37
$1.50
1주일 범위
$1.30
$1.70
52주 변동 폭
$1.30
$42.40
Autonomix Medical Inc Stock (AMIX) Company Profile
명칭
Autonomix Medical Inc
전화
832-277-7816
주소
21 WATERWAY AVENUE, SUITE 300, THE WOODLANDS
AMIX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AMIX
Autonomix Medical Inc
|
1.48 | 4.52M | 0 | 0 | 0 | 0.00 |
|
ABT
Abbott Laboratories
|
133.58 | 232.41B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
102.09 | 155.73B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
383.89 | 146.23B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
87.44 | 106.37B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
77.52 | 45.88B | 5.54B | 4.18B | 623.10M | 7.00 |
Autonomix Medical Inc 주식(AMIX)의 최신 뉴스
Autonomix set to expand cancer pain treatment trial - Investing.com India
Autonomix granted approval to expand PoC human clinical trial - TipRanks
Autonomix (AMIX) Gains Approval for New Clinical Trial Phase in Uzbekistan | AMIX Stock News - GuruFocus
Autonomix set to expand cancer pain treatment trial By Investing.com - Investing.com Nigeria
Autonomix Medical, Inc. Granted Approval to Expand Proof-of-Concept Human Clinical Study, Doubling Potential Addressable Market Beyond Pancreatic Cancer Pain - Yahoo
Autonomix Medical, Inc. (NASDAQ:AMIX) Sees Large Decrease in Short Interest - Defense World
Autonomix Medical, Inc. SEC 10-K Report - TradingView
Autonomix Medical (NASDAQ:AMIX) Stock Price Down 4.3% – What’s Next? - Defense World
AMIX Stock May Climb Following Key U.S. Patent for Nerve-Sensing Tech - MSN
Autonomix picks up key nerve ablation catheter patent - MassDevice
Autonomix granted key U.S. patent for catheter-based platform technology - TipRanks
Autonomix (AMIX) Secures New Patent for Nerve Treatment Technolo - GuruFocus
Autonomix (AMIX) Secures New Patent for Nerve Treatment Technology | AMIX Stock News - GuruFocus
Autonomix Medical, Inc. Granted Key U.S. Patent for Innovative Catheter-Based Platform Technology - The Manila Times
Breakthrough Patent: How Autonomix Medical's New Nerve-Mapping Tech Could Transform Pain Treatment - Stock Titan
Autonomix CEO Brad Hauser to Present at Virtual Investor’s Closing Bell Event - GlobeNewswire
Exclusive Live Access: Autonomix CEO Reveals Game-Changing Neural Sensing Technology to Investors - Stock Titan
Autonomix CEO outlines follow-on expansion study expected to begin in Q2 - TipRanks
Autonomix plans expansion phase for cancer pain trial - Investing.com
AMIX Expands Clinical Trials to Target Broader Cancer Pain Marke - GuruFocus
AMIX Expands Clinical Trials to Target Broader Cancer Pain Market | AMIX Stock News - GuruFocus
Autonomix plans expansion phase for cancer pain trial By Investing.com - Investing.com India
Autonomix Medical, Inc. Announces Follow-On Phase of Clinical Trial to Expand Treatment Options for Cancer Pain Management - Nasdaq
Brad Hauser, CEO of Autonomix Medical, Inc. Outlines - GlobeNewswire
Brad Hauser, CEO of Autonomix Medical, Inc. Outlines Follow-On Expansion Study Expected to Begin in Q2 2025, Potentially Doubling Addressable Market - Stock Titan
Ananda Pharma, Accsys Technologies, Autonomix Medical, BitwiseSmall Cap Week in Review - Research Tree
Autonomix Medical reports promising results in first-in-human trial for novel cancer pain therapy - Proactive financial news
Autonomix reports significant pain relief in cancer trial - Investing.com
Autonomix reports significant pain relief in cancer trial By Investing.com - Investing.com India
Autonomix Highlights Compelling Patient Testimonial Showing Rapid Pain Relief from First-in-Human Proof-of-Concept Trial in Pancreatic Cancer Pain - GlobeNewswire
Breakthrough Cancer Pain Treatment Eliminates Opioid Use in 100% of Responding Patients, Trial Shows - Stock Titan
Mariner LLC Sells 11,756 Shares of Autonomix Medical, Inc. (NASDAQ:AMIX) - Defense World
It is Poised to be a Bull Market for Autonomix Medical Inc (AMIX) - Sete News
Autonomix Medical, Inc. Announces Successful Initial Trial Phase and Plans for Market Expansion Study in Pancreatic Cancer Pain Management - Nasdaq
Autonomix Medical, Inc. (NASDAQ: AMIX) Participates in Virtual Investor 'What This Means” Segment Highlighting Key Learnings from First-In-Human Trial and Extension into Visceral Cancer Pain - The Manila Times
Autonomix Medical, Inc. (NASDAQ: AMIX) Participates in - GlobeNewswire
Autonomix Medical Pain Treatment Trial Success Leads to Cancer Market Expansion | AMIX Stock News - Stock Titan
Autonomix Medical Inc (AMIX) Outlook: Looking Back For Insights - Stocksregister
Maxim Group Initiates Coverage on Autonomix Medical (NASDAQ:AMIX) - Defense World
Maxim Initiates Coverage of Autonomix (AMIX) with Positive Outlo - GuruFocus
Autonomix (AMIX) Reports Promising Trial Results in Pancreatic C - GuruFocus
How is AMIX’s stock performing after recent trades? - uspostnews.com
Autonomix Medical Inc (AMIX) Stock: Exploring a Year of Highs, Lows, and Trading Volume - investchronicle.com
Autonomix provides update on initial phase on delivering transvascular energy - TipRanks
Autonomix (AMIX) Reports Promising Trial Results in Pancreatic Cancer Pain Treatment | AMIX Stock News - GuruFocus
Autonomix advances pain treatment in cancer trials By Investing.com - Investing.com Australia
Autonomix advances pain treatment in cancer trials - Investing.com
Autonomix Medical, Inc. Reports Positive Outcomes in Initial Phase of First-in-Human Proof-of-Concept Trial in Pancreatic Cancer Pain and Initiates Market Expansion Study for Visceral Cancer Pain - The Manila Times
Maxim Initiates Coverage of Autonomix (AMIX) with Positive Outlook | AMIX Stock News - GuruFocus
Autonomix Medical, Inc. Reports Positive Outcomes in - GlobeNewswire
Revolutionary Cancer Pain Treatment Shows 100% Success Rate: Autonomix Medical's Breakthrough Trial Results - Stock Titan
Autonomix Medical Inc (AMIX) 재무 분석
Autonomix Medical Inc (AMIX)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
0.56%
1.70%
자본화:
|
볼륨(24시간):